Moderator: Mark Sulkowski, Johns Hopkins University School of Medicine
Moderator: Man-Fung Yuen, The University of Hong Kong / Queen Mary Hospital

• 12:30 – 12:40 Brief Introduction of industry talks
• 12:40 – 12:50 Evidence of vaccine efficacy in a heterogeneous patient population
• 12:50 – 13:00 Durable HBsAg decline following a single injection of VRON-0200
• 13:00 – 13:10 Opportunities for bepirovirsen re-treatment based on modeling of existing data
• 13:10 – 13:20 Functional cure rates in treatment naive vs. treatment experienced patients receiving AHB-137
• 13:20 – 13:30 Insights into sustained HBsAg reduction after discontinuation of Pevifoscovir
• 13:30 – 13:40 Antiviral efficacy of epigenetic editor Tune-401
• 13:40 – 13:50 Antiviral efficacy of arcus nuclease, PBGENE-HBV, and editing profiles observed in patient biopsies
• 13:50 – 14:30 Discussion